Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 1997

View Archived Issues

NIH licenses method of reducing aminoglycoside-induced hearing loss

NIH licenses PTC gene for cancer diagnosis and therapy

NIH seeks licensees for method of determining susceptibility to bipolar disease

Licensees sought for diagnostic aid for AD

NIH seeks licensees for method of characterizing/screening/detecting DNA-binding ligands

Cellegy Pharmaceuticals: FY96 product highlights

Columbia Laboratories: FY96 product highlights

CV Therapeutics: FY96 product highlights

Ligand Pharmaceuticals: FY96 product highlights

Oncor: FY96 product highlights

Sheffield Medical Technologies: FY96 product highlights

Titan Pharmaceuticals: FY96 product highlights

VIMRx: FY96 product highlights

Aradigm's SmartMist covered by U.S. patent

PDL and Teijin agreement for MAb to E. coli toxin

AMBI's Cardia Salt Alternative associated with reduced blood pressure

NitroMed/J&J divisions collaborate on NSAID/NO donor compounds

Agents for cerebral ischemia and neurodegenerative disorders from Boehringer Ingelheim

SmithKline Beecham claims novel endothelin antagonists

Small-molecule drug discovery collaboration between Chiroscience and Alcon

Quinolone PDE IV/TNF inhibitors from Chiroscience

Lilly describes agents for postmenopausal syndrome

Fujisawa reports antiulcer agents

Zila completes Cygnus acquisition

Selfadministration device for Imitrex available in the U.S.

Taisho/Ikeda Mohando describe anti-H. pylori agent

Antimicrobial/antineoplastic antibiotic discovered by Ajinomoto

Sugen receives patent coverage for GRB2 cancer target

ID's strep vaccine safe and effective in animals

Mylan and Meridian reach generic drug agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.